All News

A cross-sectional analysis found diverging skin cancer trends by region, with basal cell carcinoma projected to have the highest global burden by 2050.

Demetre Daskalakis, MD, MPH, Callen-Lorde, opened the first full day of ATS 2026 by highlighting the past, present, and future of vaccine policy in the US.

Text message reminders increased CRC screening completion at 2 FQHCs, with the strongest impact seen for Cologuard use.

Black patients with breast cancer face cost, limited representation, and textured-hair concerns that reduce scalp-cooling use to prevent hair loss.

Women’s Health Month highlights major 2026 shifts in menopause care, brain health, abortion access, doula coverage, and wearable tech.

Health updates cover abortion pill access, lung care research, pregnancy-linked heart risks, US longevity gaps, and flawed drug adherence metrics.

Patients with IPF hospitalized for CDI had higher mortality, longer stays, and greater costs.

The Supreme Court’s temporary action on mifepristone telehealth access raises new questions about reproductive health policy, autonomy, and care access in the US.

Medication adherence is a key to improving outcomes, reducing costs, and strengthens the patient experience, making it an important lens into how health care is serving patients

Older adults with prior adenomas had slightly higher CRC risk, but 10-year CRC incidence was far outweighed by non-CRC mortality, supporting reduced surveillance colonoscopy use.

The disease progression of patients with MS had an association with their serum protein level.

Skin cancers arising from burn scars carry high recurrence and mortality risks, with squamous cell carcinoma considered most common.

There were about 70,000 Americans who died of drug overdoses in 2025, which continues a decline in drug overdoses that has lasted 3 years.

Exposure to adverse pregnancy outcomes may be associated with worse cardiovascular health and early arterial injury in young adulthood.

New research shows that celebrity endorsements can have a major impact on prescription patterns in the US.

A cohort-based mortality study found major state-by-state life expectancy gaps, with Southern states lagging in longevity gains.

In psoriatic arthritis, high BMI and smoking raise disease activity, while weight-focused lifestyle changes improve treat-to-target odds at one year.

New pediatric guidelines standardize radiation for metastatic rhabdomyosarcoma, detailing site-specific dosing to improve STS outcomes.

The next-generation BCL2 inhibitor is approved for adults with relapsed or refractory MCL who have received at least 2 lines of systemic treatment

Global experts have renamed PCOS to PMOS, highlighting metabolic and endocrine risks—here’s what the name change means for diagnosis and care.

From rewriting drug approval standards to embedding AI in review workflows, former FDA commissioner Marty Makary, MD reshaped how evidence, speed, and access are balanced in US drug regulation.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

The complexity of MCL calls for personalized therapeutic strategies, but prior authorization protocols may not recognize distinct patient needs.

New real-world evidence presented at PQA 2026 exposes the blind spots in how medication adherence is measured, monitored, and misunderstood.

Deborah Doroshow, MD, PhD, discusses lung cancer trial access, targeted therapy advances, and treatment gaps in part 2 of her interview.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

RBM20 truncating variants are associated with a milder, lower-penetrance form of dilated cardiomyopathy compared with other pathogenic genetic drive.

Digitalis glycosides lowered worsening heart failure events in patients with HFmrEF and HFrEF, but no mortality benefit was observed.